Based on the discussion above, it is clear that a better understanding of the PD-1/PD-L1/L2 axes in SLE and other autoimmune diseases could lead to new therapeutic strategies that can exclusively target the PD-1 pathway or can be combined with other treatments. The gene discussed is PDCD1; the disease is autoimmune disease.